AXDX RSI Chart
Last 7 days
2.3%
Last 30 days
21.6%
Last 90 days
-23.7%
Trailing 12 Months
-87.8%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 12.2M | 0 | 0 | 0 |
2023 | 12.6M | 11.7M | 12.0M | 12.1M |
2022 | 12.2M | 13.3M | 13.1M | 12.8M |
2021 | 11.3M | 12.0M | 11.5M | 11.8M |
2020 | 9.9M | 10.2M | 11.5M | 11.2M |
2019 | 6.6M | 6.7M | 7.6M | 9.3M |
2018 | 4.4M | 5.4M | 6.0M | 5.7M |
2017 | 613.0K | 1.3M | 2.1M | 4.2M |
2016 | 224.0K | 226.0K | 229.0K | 246.0K |
2015 | 122.0K | 127.0K | 132.0K | 75.0K |
2014 | 46.0K | 52.0K | 55.0K | 122.0K |
2013 | 80.0K | 41.0K | 48.2K | 48.0K |
2012 | 241.7K | 238.8K | 236.0K | 158.0K |
2011 | 0 | 0 | 244.5K | 243.1K |
2010 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 17, 2024 | phillips jack | acquired | - | - | 59,928 | chief executive officer |
Apr 17, 2024 | phillips jack | sold | -20,853 | 0.78 | -26,735 | chief executive officer |
Apr 12, 2024 | phillips jack | acquired | - | - | 59,928 | chief executive officer |
Apr 12, 2024 | phillips jack | sold | -22,828 | 0.86 | -26,545 | chief executive officer |
Apr 09, 2024 | mertz larry michael | sold | -12,166 | 0.87 | -13,984 | chief technology officer |
Apr 09, 2024 | patience david | acquired | - | - | 37,468 | chief financial officer |
Apr 09, 2024 | mertz larry michael | acquired | - | - | 40,633 | chief technology officer |
Apr 09, 2024 | patience david | sold | -11,567 | 0.87 | -13,296 | chief financial officer |
Apr 04, 2024 | phillips jack | sold | -13,980 | 0.88 | -15,887 | chief executive officer |
Apr 04, 2024 | mertz larry michael | acquired | - | - | 2,866 | chief technology officer |
Which funds bought or sold AXDX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | STATE STREET CORP | reduced | -13.26 | -72,046 | 20,211 | -% |
May 15, 2024 | Tudor Investment Corp Et Al | unchanged | - | -41,354 | 13,973 | -% |
May 15, 2024 | MORGAN STANLEY | reduced | -12.85 | -4,757 | 1,342 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | reduced | -0.41 | -5,766 | 1,937 | -% |
May 15, 2024 | Steward Partners Investment Advisory, LLC | unchanged | - | -1,201 | 406 | -% |
May 15, 2024 | ARMISTICE CAPITAL, LLC | new | - | 1,827,540 | 1,827,540 | 0.02% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 90.96 | -8,776 | 8,174 | -% |
May 15, 2024 | Alyeska Investment Group, L.P. | new | - | 79,742 | 79,742 | -% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | added | 33.11 | -36,293 | 18,379 | -% |
May 15, 2024 | ORACLE INVESTMENT MANAGEMENT INC | reduced | -62.27 | -395,694 | 41,680 | 0.03% |
Unveiling Accelerate Diagnostics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Accelerate Diagnostics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
ABT | 181.0B | 40.3B | 32.18 | 4.49 | ||||
BDX | 68.3B | 19.7B | 51.24 | 3.46 | ||||
ALGN | 20.4B | 3.9B | 44.2 | 5.22 | ||||
BAX | 18.0B | 14.9B | 6.79 | 1.21 | ||||
MID-CAP | ||||||||
ATR | 9.8B | 3.5B | 31.27 | 2.76 | ||||
HSIC | 9.6B | 12.5B | 24.63 | 0.77 | ||||
BIO | 8.4B | 2.6B | -26.02 | 3.22 | ||||
XRAY | 5.9B | 3.9B | -62.84 | 1.49 | ||||
AXNX | 3.4B | 387.1M | -216.3 | 8.9 | ||||
PDCO | 2.3B | 6.6B | 11.93 | 0.35 | ||||
SMALL-CAP | ||||||||
AHCO | 1.3B | 3.2B | -1.91 | 0.41 | ||||
ANIK | 376.6M | 169.3M | -4.9 | 2.23 | ||||
ANGO | 241.9M | 324.0M | -1.26 | 0.75 | ||||
APYX | 56.1M | 50.5M | -2.46 | 1.11 | ||||
AEMD | 1.0M | 3.7M | -0.09 | 0.28 |
Accelerate Diagnostics Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -3.5% | 2,921,000 | 3,027,000 | 3,299,000 | 2,921,000 | 2,812,000 | 2,973,000 | 2,960,000 | 3,861,000 | 2,958,000 | 3,344,000 | 3,122,000 | 2,798,000 | 2,518,000 | 3,110,000 | 3,588,000 | 2,125,000 | 2,342,000 | 3,470,000 | 2,271,000 | 1,806,000 | 1,750,000 |
Gross Profit | 14.2% | 723,000 | 633,000 | 107,000 | 799,000 | 1,011,000 | 842,000 | 579,000 | 1,080,000 | 802,000 | -3,317,000 | 986,000 | 1,053,000 | 897,000 | 1,149,000 | 1,301,000 | 954,000 | 1,055,000 | 1,513,000 | 1,154,000 | 899,000 | 834,000 |
Costs and Expenses | -4.3% | 10,879,000 | 11,363,500 | 14,757,000 | 13,384,000 | 17,073,000 | 14,801,500 | 15,540,000 | 19,069,000 | 16,697,000 | 16,094,000 | 15,518,000 | 18,643,000 | 20,924,000 | 16,229,500 | 16,466,000 | 16,679,000 | 18,785,000 | 19,783,000 | 18,807,000 | 18,986,000 | 19,656,000 |
S&GA Expenses | -1.5% | 5,706,000 | 5,794,000 | 7,761,000 | 7,564,000 | 10,105,000 | 8,771,500 | 8,255,000 | 11,493,000 | 10,673,000 | 11,491,500 | 10,806,000 | 12,910,000 | 14,029,000 | 11,165,000 | 11,465,000 | 11,332,000 | 12,943,000 | 13,583,500 | 12,743,000 | 12,837,000 | 12,723,000 |
R&D Expenses | -7.1% | 5,173,000 | 5,569,500 | 6,996,000 | 5,820,000 | 6,968,000 | 6,030,000 | 7,285,000 | 7,576,000 | 6,024,000 | 4,602,500 | 4,712,000 | 5,733,000 | 6,895,000 | 5,064,500 | 5,001,000 | 5,347,000 | 5,842,000 | 6,199,500 | 6,064,000 | 6,149,000 | 6,933,000 |
EBITDA Margin | 4.5% | -4.54 | -4.76 | -4.98 | -6.55 | -4.89 | -4.47 | -5.28 | -4.42 | -4.80 | -5.67 | -5.71 | -6.32 | -6.49 | - | - | - | - | - | - | - | - |
Interest Expenses | -91.8% | 10,000 | 122,000 | - | - | - | - | 351,500 | 713,000 | 1,506,000 | -4,095,000 | 4,211,000 | 4,177,000 | 4,090,000 | -7,251,500 | 3,955,000 | 3,835,000 | 3,749,000 | 3,671,000 | 3,598,000 | 3,528,000 | 3,459,000 |
Income Taxes | -100.0% | - | 563,500 | 131,000 | 156,000 | - | -77,000 | - | - | - | 45,000 | - | - | - | 5,000 | - | - | - | -110,500 | -239,000 | 17,000 | 221,000 |
Earnings Before Taxes | -14.5% | -14,230,000 | -12,432,000 | 1,041,000 | -32,579,000 | -16,800,000 | -14,686,000 | -15,896,000 | -18,523,000 | -13,465,000 | -22,758,000 | -8,986,000 | -21,674,000 | -24,239,000 | -18,907,000 | -18,757,000 | -19,230,000 | -21,309,000 | -21,445,500 | -20,673,000 | -20,798,000 | -21,500,000 |
EBT Margin | 5.1% | -4.78 | -5.04 | -5.25 | -6.85 | -5.23 | -4.91 | -5.38 | -4.80 | -5.47 | -6.59 | -6.39 | -6.96 | -7.15 | - | - | - | - | - | - | - | - |
Net Income | -9.5% | -14,230,000 | -12,998,000 | 910,000 | -32,735,000 | -16,795,000 | -14,609,000 | -15,896,000 | -18,523,000 | -13,465,000 | -22,803,000 | -8,986,000 | -21,674,000 | -24,239,000 | -18,912,000 | -18,757,000 | -19,230,000 | -21,309,000 | -21,335,000 | -20,434,000 | -20,815,000 | -21,721,000 |
Net Income Margin | 5.0% | -4.85 | -5.11 | -5.27 | -6.86 | -5.22 | -4.90 | -5.39 | -4.80 | -5.48 | -6.59 | -6.39 | -6.96 | -7.15 | - | - | - | - | - | - | - | - |
Free Cashflow | -9.0% | -8,452,000 | -7,755,000 | -8,314,266 | -10,906,266 | -13,440,266 | -9,623,266 | -13,646,266 | -13,072,266 | -12,679,266 | -12,020,266 | -12,521,266 | -9,626,266 | -13,448,266 | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -2.1% | 31.00 | 31.00 | 39.00 | 50.00 | 51.00 | 65.00 | 76.00 | 59.00 | 70.00 | 83.00 | 81.00 | 94.00 | 93.00 | 93.00 | 104 | 115 | 120 | 134 | 147 | 159 | 172 |
Current Assets | -1.4% | 24.00 | 24.00 | 32.00 | 42.00 | 43.00 | 56.00 | 66.00 | 48.00 | 61.00 | 73.00 | 72.00 | 84.00 | 82.00 | 82.00 | 92.00 | 103 | 107 | 122 | 134 | 150 | 164 |
Cash Equivalents | 20.3% | 15.00 | 12.00 | 20.00 | 29.00 | 29.00 | 35.00 | 39.00 | 5.00 | 14.00 | 40.00 | 36.00 | 45.00 | 43.00 | 36.00 | 27.00 | 47.00 | 39.00 | 61.00 | 93.00 | 87.00 | 75.00 |
Inventory | -1.8% | 3.00 | 3.00 | 4.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 6.00 | 5.00 | 10.00 | 10.00 | 10.00 | 9.00 | 9.00 | 9.00 | 9.00 | 8.00 | 8.00 | 8.00 | 9.00 |
Net PPE | 33.8% | 3.00 | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 4.00 | 4.00 | 5.00 | 5.00 | 5.00 | 6.00 | 6.00 | 6.00 | 7.00 | 8.00 | 9.00 | 8.00 | 9.00 | 8.00 | 7.00 |
Liabilities | 10.2% | 57.00 | 51.00 | 74.00 | 89.00 | 90.00 | 87.00 | 86.00 | 121 | 126 | 118 | 121 | 164 | 159 | 156 | 154 | 152 | 143 | 142 | 137 | 133 | 129 |
Current Liabilities | 34.0% | 16.00 | 12.00 | 38.00 | 54.00 | 68.00 | 67.00 | 66.00 | 67.00 | 114 | 7.00 | 8.00 | 9.00 | 7.00 | 7.00 | 7.00 | 10.00 | 7.00 | 8.00 | 6.00 | 8.00 | 6.00 |
Long Term Debt | - | - | - | - | - | - | - | - | 50.00 | 9.00 | 108 | 110 | 147 | 144 | 141 | 138 | 135 | 133 | 130 | 127 | 125 | 122 |
LT Debt, Current | 0% | 1.00 | 1.00 | 1.00 | 1.00 | 57.00 | 56.00 | 56.00 | 56.00 | 106 | - | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | - | - | - | - | - |
LT Debt, Non Current | - | - | - | - | - | - | - | - | 50.00 | 9.00 | 108 | 110 | 147 | 144 | 141 | 138 | 135 | 133 | 130 | 127 | 125 | 122 |
Shareholder's Equity | -29.6% | -25.78 | -19.89 | - | - | 0.00 | -22.26 | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 475 | - | 463 | 458 | - | 10.00 | 26.00 | 43.00 |
Retained Earnings | -2.1% | -683 | -668 | -655 | -656 | -624 | -607 | -592 | -576 | -558 | -570 | -547 | -538 | -517 | -492 | -474 | -455 | -436 | -414 | -393 | -372 | -352 |
Additional Paid-In Capital | 1.2% | 703 | 695 | 666 | 664 | 631 | 630 | 628 | 560 | 547 | 581 | 553 | 514 | 496 | 475 | 469 | 463 | 458 | 452 | 449 | 444 | 440 |
Shares Outstanding | 48.7% | 22.00 | 15.00 | 15.00 | 14.00 | 10.00 | 10.00 | 8.00 | 7.00 | 7.00 | 6.00 | 6.00 | 6.00 | 6.00 | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 61.00 | - | - | - | 53.00 | - | - | - | 320 | - | - | - | 480 | - | - | - | 714 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -9.0% | -8,452 | -7,755 | -8,241 | -10,833 | -13,367 | -9,550 | -13,573 | -12,999 | -12,606 | -11,947 | -12,448 | -9,553 | -13,375 | -10,343 | -12,656 | -9,798 | -17,597 | -13,865 | -17,367 | -14,057 | -19,505 |
Share Based Compensation | -4.9% | 1,297 | 1,364 | 1,815 | 1,653 | 555 | 2,446 | 1,229 | 3,971 | 2,979 | 2,989 | 3,629 | 6,590 | 8,839 | 4,173 | 4,676 | 3,416 | 4,199 | 3,209 | 3,131 | 2,881 | 3,397 |
Cashflow From Investing | -366.4% | -513 | -110 | -354 | 915 | 8,209 | 5,842 | 15,788 | 4,428 | -13,641 | -2,750 | 2,789 | -257 | 8,522 | 17,852 | -9,938 | 11,048 | -5,356 | -18,653 | 21,294 | 25,371 | 24,799 |
Cashflow From Financing | 10590.7% | 11,439 | 107 | -817 | 9,806 | -77.00 | -126 | 32,036 | -357 | 77.00 | 18,891 | 830 | 11,650 | 11,855 | 1,340 | 2,255 | 6,609 | 1,429 | 581 | 1,622 | 804 | 3,816 |
Buy Backs | - | - | - | - | - | - | - | - | - | - | 20,294 | 3.00 | - | - | - | - | - | - | - | - | - | - |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Net sales | $ 2,921,000 | $ 2,812,000 |
Cost of sales | 2,198,000 | 1,801,000 |
Gross profit | 723,000 | 1,011,000 |
Costs and expenses: | ||
Research and development | 5,173,000 | 6,968,000 |
Sales, general and administrative | 5,706,000 | 10,105,000 |
Total costs and expenses | 10,879,000 | 17,073,000 |
Loss from operations | (10,156,000) | (16,062,000) |
Other income (expense): | ||
Loss on fair value adjustments | (1,216,000) | 0 |
Foreign currency exchange gain | 19,000 | 233,000 |
Interest income | 200,000 | 420,000 |
Other (expense) income, net | (627,000) | 45,000 |
Total other expense, net | (4,074,000) | (733,000) |
Net loss before income taxes | (14,230,000) | (16,795,000) |
Provision for income taxes | 0 | 0 |
Net loss | $ (14,230,000) | $ (16,795,000) |
Basic net loss per share (in usd per share) | $ (0.74) | $ (1.71) |
Diluted net loss per share (in usd per share) | $ (0.74) | $ (1.71) |
Basic weighted average shares outstanding (in shares) | 19,216 | 9,830 |
Diluted weighted average shares outstanding (in shares) | 19,216 | 9,830 |
Other comprehensive loss: | ||
Net loss | $ (14,230,000) | $ (16,795,000) |
Net unrealized gain on debt securities available-for-sale | 0 | 24,000 |
Foreign currency translation adjustment | (6,000) | (255,000) |
Comprehensive loss | (14,236,000) | (17,026,000) |
Nonrelated Party | ||
Other income (expense): | ||
Interest expense | (2,450,000) | (418,000) |
Related Party | ||
Other income (expense): | ||
Interest expense | $ 0 | $ (1,013,000) |
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 14,606 | $ 12,138 |
Investments | 1,145 | 1,081 |
Trade accounts receivable, net | 2,217 | 2,622 |
Inventory | 3,249 | 3,310 |
Prepaid expenses | 1,068 | 380 |
Purchase obligation put option asset | 0 | 3,419 |
Other current assets | 1,848 | 1,516 |
Total current assets | 24,133 | 24,466 |
Property and equipment, net | 3,197 | 2,389 |
Finance lease assets, net | 1,225 | 1,518 |
Operating lease right of use assets, net | 957 | 1,177 |
Other non-current assets | 1,210 | 1,816 |
Total assets | 30,722 | 31,366 |
Current liabilities: | ||
Accounts payable | 5,108 | 4,796 |
Accrued liabilities | 3,351 | 3,243 |
Accrued interest | 1,014 | 164 |
Deferred revenue and income, current | 1,272 | 1,545 |
Current portion of convertible notes | 726 | 726 |
Common warrant liability | 3,035 | 0 |
Finance lease, current | 685 | 583 |
Operating lease, current | 940 | 977 |
Total current liabilities | 16,131 | 12,034 |
Finance lease, non-current | 81 | 262 |
Operating lease, non-current | 328 | 570 |
Deferred income, non-current | 1,110 | 1,122 |
Other non-current liabilities | 1,197 | 1,164 |
Convertible notes, non-current | 37,655 | 36,102 |
Total liabilities | 56,502 | 51,254 |
Commitments and contingencies (see Note 14) | ||
Stockholders’ deficit: | ||
Preferred shares, $0.001 par value; $5,000,000 preferred shares authorized with no shares issued and outstanding on March 31, 2024 and December 31, 2023 | 0 | 0 |
Common stock, $0.001 par value; $450,000,000 common shares authorized with 21,811,706 shares issued and outstanding on March 31, 2024 and 14,569,500 shares issued and outstanding on December 31, 2023 | 21 | 14 |
Contributed capital | 702,971 | 694,634 |
Treasury stock | (45,067) | (45,067) |
Accumulated deficit | (683,087) | (668,857) |
Accumulated other comprehensive loss | (618) | (612) |
Total stockholders’ deficit | (25,780) | (19,888) |
Total liabilities and stockholders’ deficit | $ 30,722 | $ 31,366 |